

January 11, 2019

TAKE/BSE/2018-19

The Manager
Dept. of Corporate Services-Listing
Bombay Stock Exchange Limited,
P. J. Towers, Dalal Street,
Mumbai - 400001
Scrip Code: 532890

TAKE/NSE/2018-19

The Manager-Listing Department
National Stock Exchange of India Limited
Exchange Plaza,
Bandra - Kurla Complex, Bandra (East),
Mumbai - 400051
Symbol: TAKE

Sir/ Madam,

Sub: Intimation regarding proposed acquisition(s).

With reference to the captioned subject, please take note about the proposed acquisitions by TAKE Solutions Ltd, in terms of SEBI (Listing and Disclosure Obligation Requirements) Regulations, 2015, read with SEBI circular No. CIR/CFD/CMD/4/2015 dated 9th September 2015. The requisite details under said circular are attached herewith as Annexure – I and II of this intimation.

We request you to take note of the aforesaid and acknowledge receipt.

Yours sincerely,

For TAKE Solutions Limited


Avaneesh Singh
Company Secretary



Encl: As Above

Details of acquisition of KAI Research

S.No	Particulars	Details
a)	Name of the target entity and its brief details	KAI Research KAI is a US based niche Full service CRO and health research company
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired?	No.
c)	Industry to which the entity belongs	The target entity is in Life sciences industry and is a Clinical Research Organization.
d)	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	With this acquisition, TAKE acquires Phase II and III capabilities in North America adding to its current service offerings in Europe & Asia. The company has some differentiated offerings by way of patient registries and e-clinical solutions KAI strengthens our therapeutic expertise mental health, musculoskeletal diseases, CNS, infectious diseases, Oncology and medical devices. The target has long-standing relationships with clinical sites and trusted network of service providers.
e)	Any Governmental or regulatory approvals required for the acquisition	None.
f)	Indicative time period for completion of the acquisition	The acquisition is expected to close by January 2019, subject to customary closing conditions.
g)	Nature of Consideration- whether cash consideration or shares swap and details of the same	Cash
h)	Cost of acquisition or the price at which the shares are acquired	The total consideration for this transaction shall be up to USD 27 million, including contingent payments subject to certain financial milestones

i)	Percentage of shareholding / control acquired and /or number of shares acquired	100%.
j)	Brief background about the entity acquired in terms of products /line of business acquired date of incorporation, history of last 3 years of turnover, country in which the entity has presence and any other significant information (in brief)	KAI was founded in 1986 and is based in Maryland, USA. The entity brings top of class offerings in three key areas: Clinical Trial Management, Clinical Research Consultation, and Data Management & Standardization. The entity has more than 30 years of experience in mental health, musculoskeletal diseases, neurology/CNS, and infectious diseases. The entity's staff is very experienced with over 66% being PhDs or MD/PhD and postgraduates in science. The revenues for the last three Financial years are as follows: • FY ended December 31, 2015 – USD 8.1 Million • FY ended December 31, 2016 – USD 8.9 Million • FY ended December 31, 2017 – USD 10.5 Million

Annexure - II

Details of acquisition DataCeutics

S.No	Particulars	Details
a)	Name of the target entity and its brief details	DataCeutics is a specialty Clinical Functional Service Provider based in the USA, headquartered in Philadelphia, USA The company provides quality SAS based statistical programming, clinical reporting and clinical data management programming.
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired?	No.
c)	Industry to which the entity belongs	The target entity is in Life sciences industry. It provides Clinical Data Management services to the pharmaceutical industry.
d)	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	This acquisition strengthens TAKE's domain strength in Data Sciences specific to Life Sciences enabling us to partner with our clients providing much higher value adds in their Go-To-Market strategy in terms of time, technology, and ease of change management to pharma & biotech companies that need to embrace emerging data sources that need a higher level of digital maturity. This acquisition also adds to the depth of our Top-Pharma relationships in the US geography The addition to our team, 63% of whom are highly qualified with Doctoral or Masters degrees, also strengthens our Therapeutic experience in Oncology, CNS, Cardio-vascular, Neurology, Immunology. This acquisition would enable TAKE to offer more flexible and differentiated

		business operating models to its clientele.
e)	Any Governmental or regulatory approvals required for the acquisition	None.
f)	Indicative time period for completion of the acquisition	The acquisition is expected to close by February 2019, subject to customary closing conditions.
g)	Nature of Consideration- whether cash consideration or shares swap and details of the same	Cash
h)	Cost of acquisition or the price at which the shares are acquired	The total consideration for this transaction shall be up to USD 45 million, including contingent payments subject to certain financial milestones.
i)	Percentage of shareholding / control acquired and /or number of shares acquired	100%
j)	Brief background about the entity acquired in terms of products /line of business acquired date of incorporation, history of last 3 years of turnover, country in which the entity has presence and any other significant information (in brief)	DataCeutics was founded in 1993 and is based in Philadelphia, USA. The company has core FSP experience in Oncology, CNS, Cardio-vascular, Neurology, Immunology etc. The revenues for the last three Financial years are as follows: • FY ended December 31, 2015 – USD 18.7 Million • FY ended December 31, 2016 – USD 20.1 Million • FY ended December 31, 2017 – USD 20.9 Million